MCO:NYSEMoody's Corporation Analysis
Data as of 2026-05-21 - not real-time
$444.27
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Moody's Corporation posted $7.87 bn of revenue with an 8.1% YoY growth rate and ultra‑high profitability—gross margin of 74% and operating margin of 45%—driving an exceptional ROE of 71% despite a leveraged balance sheet. The company generated $3.08 bn of operating cash flow and $2.27 bn of free cash flow, comfortably covering its 27.6% dividend payout and supporting the 0.93% yield. However, the stock trades at a forward PE of 23.9x versus an industry average of 16.7x and a price‑to‑book of 25.9x, while the DCF model suggests a fair value near $201, indicating the market is pricing a significant premium. Technical indicators are mixed: the price of $444 sits below the 20‑day SMA ($449) but above the 50‑day SMA ($444), the RSI is neutral at 48.8, and the MACD is bearish, placing short‑term momentum on the downside, though the broader trend remains neutral with support at $426 and resistance at $470. Analyst sentiment is bullish, with a “buy” consensus, a median price target of $533 and an implied upside of roughly 20%, reinforced by recent earnings beat and a dividend increase. Material news highlights continued confidence from high‑profile investors, a recent analyst target cut by Mizuho after the earnings beat, and the upcoming dividend payment, all of which add short‑term catalyst potential.
Overall, Moody's combines a resilient, high‑margin business and strong cash generation with a premium valuation and modest short‑term technical weakness, suggesting a buy‑and‑hold approach for investors seeking growth‑oriented exposure with dividend income.
Overall, Moody's combines a resilient, high‑margin business and strong cash generation with a premium valuation and modest short‑term technical weakness, suggesting a buy‑and‑hold approach for investors seeking growth‑oriented exposure with dividend income.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bearish MACD and price below 20‑day SMA
- Proximity to support at $426
- Upcoming dividend provides near‑term income
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Strong earnings growth and high margins
- Analyst consensus upside of ~20%
- Sustainable dividend with low payout ratio
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Durable franchise with recurring credit‑rating and analytics revenue
- High ROE and cash‑flow generation supporting long‑term value
- Enduring confidence from investors like Warren Buffett
Key Metrics & Analysis
Financial Health
Revenue Growth8.10%
Profit Margin31.69%
P/E Ratio31.8
ROE71.36%
ROA14.82%
Debt/Equity235.54
P/B Ratio25.9
Op. Cash Flow$3.1B
Free Cash Flow$2.3B
Industry P/E16.7
Technical Analysis
TrendNeutral
RSI48.8
Support$426.21
Resistance$470.64
MA 20$449.41
MA 50$443.73
MA 200$479.53
MACDBearish
VolumeStable
Fear & Greed Index90.13
Valuation
Fair Value$200.96
Target Price$536.00
Upside/Downside20.65%
GradeOvervalued
TypeBlend
Dividend Yield0.93%
Risk Assessment
Beta0.78
Volatility27.19%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.